Full Press Release Details
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year MRD revenue growth of 46% driven by clonoSEQ testing volume
SEATTLE, January 12, 2026 - (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT),
a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year
ended December 31, 2025.
"2025 was a pivotal year for Adaptive, marked by accelerating
momentum across our MRD business driven by strong growth in clonoSEQ adoption," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we look ahead to 2026, we
are well-positioned to extend our leadership in MRD testing, sustain strong clonoSEQ volume and ASP growth, and further expand MRD profitability."
Adaptive Biotechnologies plans to release its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.
Forward-Looking Statements
All statements contained in
this press release other than statements of historical fact are forward-looking statements, including statements regarding Adaptive's financial results for the fourth quarter and full year ended December 31, 2025 and its goals and
strategies for 2026. In some cases, you can identify forward-looking statements by the words "may," "expect," "plan," "believe," "estimate," "predict," "project,"
"continue," or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a
combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate.
In particular, with respect to our preliminary financial results for the fourth quarter and full year ended
December 31, 2025, we have not completed preparation of our financial statements for the fourth quarter or full year of 2025. The revenue, cash, test volumes and other results presented herein are preliminary and unaudited and are thus
inherently uncertain and subject to change as Adaptive completes its customary year-end close, prepares its financial statements and completes the audit thereof. This press release does not disclose estimated
expenses, although we expect fourth quarter and full year 2025 net loss to decrease compared to comparable periods in 2024. The final results for the fourth quarter and full year ended December 31, 2025 may differ materially from these
estimates. Adaptive's expectations with respect to its preliminary, unaudited results herein are based upon management estimates and are the responsibility of management. Adaptive's independent registered public accounting firm has not
audited, reviewed or performed any procedures with respect to these preliminary results.
The forward-looking statements in this press release represent
our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Adaptive Biotechnologies
Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on
harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the
inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We
apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical
pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Karina Calzadilla, Vice President,
Investor Relations and FP&A
Erica Jones, Associate Corporate Communications Director